NECTIN4 Amplification Is a Frequent Event in Central Nervous System Metastases of Urothelial Carcinoma
We found that tumor samples from patients with cancer of the urinary tract that had spread to the brain had higher expression of a gene called NECTIN4 (67%). Our findings suggest that treatments targeting NECTIN4, such as a drug called enfortumab vedotin with or without pembrolizumab, might benefit patients with brain metastases, especially if their tumors have high NECTIN4 levels.
Authors
- Michael Hölzel
- Julian Heidenreich
- Thomas Büttner (ORCID: https://orcid.org/0000-0003-0316-9621)
- Tobias Blau (ORCID: https://orcid.org/0000-0003-0439-971X)
- Teresa Schmidt (ORCID: https://orcid.org/0000-0003-2434-8223)
- Florian Schmid (ORCID: https://orcid.org/0000-0002-0862-5027)
- M. Eckstein
- Yuri Tolkach (ORCID: https://orcid.org/0000-0001-5239-2841)
- Thomas Stehlé (ORCID: https://orcid.org/0000-0001-9828-3245)
- Constantin Rieger (ORCID: https://orcid.org/0009-0000-3993-7974)
- V. Grünwald
- Martin Glas
- Niklas Klümper
- Kathy Keyvani
- Axel Heidenreich
- Richard Weiten
Institutions
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- University Hospital Bonn (DE)
- Universitätsklinikum Erlangen (DE)
- Katholisches Klinikum Lünen/Werne , St.-Marien-Hospital Lünen (DE)
- University Hospital of Zurich (CH)
- Essen University Hospital (DE)
- University Hospital Cologne (DE)
- University of Duisburg-Essen (DE)
- Medical University of Vienna (AT)
Publication Details
- Journal
- European Urology Open Science
- Published
- 2026-02-21
- DOI
- https://doi.org/10.1016/j.euros.2026.02.009
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00